Roche Reports Positive Results from Breast Cancer Drug Trial

The study results revealed that patients receiving T-DM1 lived significantly longer with their disease under control and experienced fewer side effects typical of chemotherapy.

Roche has reported positive topline results from its first randomised trial of trastuzumab emtansine (T-DM1), an antibody-drug conjugate, in HER2-positive metastatic breast cancer. The study results revealed that patients receiving T-DM1 lived significantly longer with their disease under control and experienced fewer side effects typical of chemotherapy.

The randomised, multicentre international, two-arm and open-label clinical trial was designed to compare T-DM1 single agent to the combination of Herceptin (trastuzumab) and chemotherapy (docetaxel) in previously untreated patients.

The trial enrolled 137 patients with first-line HER2-positive metastatic breast cancer from approximately 64 sites, who were randomised to receive either T-DM1 or Her